Velcalcetide (AMG 416), a novel peptide agonist of the calcium-sensing receptor, reduces serum parathyroid hormone and FGF23 levels in healthy male subjects (Q34385273)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Velcalcetide (AMG 416), a novel peptide agonist of the calcium-sensing receptor, reduces serum parathyroid hormone and FGF23 levels in healthy male subjects	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

1 August 2017

Velcalcetide (AMG 416), a novel peptide agonist of the calcium-sensing receptor, reduces serum parathyroid hormone and FGF23 levels in healthy male subjects (English)

1 reference

Europe PubMed Central

1 August 2017

author name string

Kevin J Martin

1

1 reference

Europe PubMed Central

1 August 2017

Gregory Bell

2

1 reference

Europe PubMed Central

1 August 2017

Karen Pickthorn

3

1 reference

Europe PubMed Central

1 August 2017

Saling Huang

4

1 reference

Europe PubMed Central

1 August 2017

Andrew Vick

5

1 reference

Europe PubMed Central

1 August 2017

Peter Hodsman

6

1 reference

Europe PubMed Central

1 August 2017

Munro Peacock

7

1 reference

Europe PubMed Central

1 August 2017

language of work or name

0 references

publication date

13 November 2013

1 reference

Europe PubMed Central

1 August 2017

Nephrology Dialysis Transplantation

1 reference

Europe PubMed Central

1 August 2017

29

1 reference

Europe PubMed Central

1 August 2017

2

1 reference

Europe PubMed Central

1 August 2017

385-392

1 reference

Europe PubMed Central

1 August 2017

copyright license

Creative Commons Attribution-NonCommercial 3.0 Unported

6 October 2016

1 reference

April 2022 Public Data File from Crossref

copyright status

0 references

FGF23 induces left ventricular hypertrophy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3910343

6 July 2018

Secondary hyperparathyroidism: pathogenesis, disease progression, and therapeutic options.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3910343

6 July 2018

Effect of paricalcitol and cinacalcet on serum phosphate, FGF-23, and bone in rats with chronic kidney disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3910343

6 July 2018

Effects of cinacalcet and concurrent low-dose vitamin D on FGF23 levels in ESRD.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3910343

6 July 2018

Clinical pharmacokinetic and pharmacodynamic profile of cinacalcet hydrochloride

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3910343

6 July 2018

Fibroblast growth factor 23 and left ventricular hypertrophy in chronic kidney disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3910343

6 July 2018

Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3910343

6 July 2018

Area under the curve and other summary indicators of repeated waking cortisol measurements

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3910343

6 July 2018

Cinacalcet hydrochloride maintains long-term normocalcemia in patients with primary hyperparathyroidism

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3910343

6 July 2018

Calcium-sensing receptor in the brain.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3910343

6 July 2018

The consequences of uncontrolled secondary hyperparathyroidism and its treatment in chronic kidney disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3910343

6 July 2018

Targeted ablation of Fgf23 demonstrates an essential physiological role of FGF23 in phosphate and vitamin D metabolism

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3910343

6 July 2018

The calcimimetic cinacalcet normalizes serum calcium in subjects with primary hyperparathyroidism

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3910343

6 July 2018

Pharmacodynamics of the Type II Calcimimetic Compound Cinacalcet HCl

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3910343

6 July 2018

Drug delivery strategy utilizing conjugation via reversible disulfide linkages: role and site of cellular reducing activities

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3910343

6 July 2018

Primary hyperparathyroidism and the kidney: biochemical and clinical spectrum.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3910343

6 July 2018

Fibroblast growth factor (FGF)-23 inhibits renal phosphate reabsorption by activation of the mitogen-activated protein kinase pathway

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3910343

6 July 2018

The extracellular calcium-sensing receptor: its role in health and disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3910343

6 July 2018

Cloning and characterization of an extracellular Ca(2+)-sensing receptor from bovine parathyroid

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3910343

6 July 2018

Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFT417

21 January 2018

Assessment of adherence to cinacalcet by prescription refill rates in hemodialysis patients

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFT417

21 January 2018

Pharmacology of AMG 416 (Velcalcetide), a novel peptide agonist of the calcium-sensing receptor, for the treatment of secondary hyperparathyroidism in hemodialysis patients

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFT417

21 January 2018

A randomized, double-blind, placebo-controlled study to assess the efficacy and safety of cinacalcet HCl in participants with CKD not receiving dialysis

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFT417

21 January 2018

Total parathyroidectomy reduces elevated circulating fibroblast growth factor 23 in advanced secondary hyperparathyroidism.

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFT417

21 January 2018

Peripheral vascular calcification in long-haemodialysis patients: associated factors and survival consequences

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFT417

21 January 2018

Identification of calcium sensing receptor (CaSR) mRNA-expressing cells in normal and injured rat brain

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFT417

21 January 2018

AMG 416 (velcalcetide) is a novel peptide for the treatment of secondary hyperparathyroidism in a single-dose study in hemodialysis patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3910343

27 October 2018

Cinacalcet treatment and serum FGF23 levels in haemodialysis patients with secondary hyperparathyroidism

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3910343

27 October 2018

Can calcimimetics inhibit parathyroid hyperplasia? Evidence from preclinical studies

1 reference

https://pubmed.ncbi.nlm.nih.gov/24235081

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Fibroblast Growth Factor 23 (FGF23) Predicts Progression of Chronic Kidney Disease: The Mild to Moderate Kidney Disease (MMKD) Study

1 reference

https://pubmed.ncbi.nlm.nih.gov/24235081

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1093/NDT/GFT417

1 reference

Europe PubMed Central

1 August 2017

1 reference

Europe PubMed Central

1 August 2017

1 reference

Europe PubMed Central

1 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q34385273&oldid=1971774320"